Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Net Income history
Currency unavailable · from the cash flow
No Net Income data reported for this period type.
Net Income vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M USD | +92.9% | +29.5% | 5933.5% |
| LTM Sep 2026 | $263.86M USD | +77.1% | +22.8% | 291.6% | |
| LTM Jun 2026 | $213.06M USD | +309.4% | +0.7% | 75.6% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $152.57M USD | +50.1% | +119.8% | — |
| LTM Mar 2026 | $104.29M USD | +8.2% | -6.9% | — | |
| LTM Mar 2026 | $69.66M USD | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | $26.79M USD | -81.0% | — | 11.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +50.1% | +11.8% | 291.6% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.